Soluble CD30 As A Surrogate Marker Of HIV-1 RNA

Value Proposition

Antiretroviral therapy (ART) has substantially reduced the morbidity and mortality rates of HIV-1 infection, the persistence of viral reservoirs continues to prevent the elimination of HIV-1 from all tissue compartments. Consequently, there is still a need for point of care (POC) tests of circulating HIV levels (viral load) that do not rely on expensive technologies such as PCR.

Technology Description

UCSF Investigators have identified CD30, a stable, soluble protein as a surrogate biomarker for HIV-1 RNA, and are developing a POC assay for widespread distribution and use.

Related Materials

• Peluso, M. J., Thanh, C., Prator, C. A., Hogan, L. E., Arechiga, V. M., Stephenson, S., Norris, P. J., Germanio, C. D., Fuchs, D., Zetterberg, H., Deeks, S. G., Magnus Gisslén, Price, R. W., & Henrich, T. J. (2020). Cerebrospinal fluid soluble CD30 elevation despite suppressive antiretroviral therapy in individuals living with HIV-1. Journal of Virus Eradication, 6(1), 19–26.
• Prator, C. A., Thanh, C., Kumar, S., Pan, T., Peluso, M. J., Bosch, R. J., Jones, N., Milush, J. M., Bakkour, S., Stone, M., Busch, M. P., Deeks, S. G., Hunt, P. W., & Henrich, T. J. (2019). Circulating CD30+CD4+ T Cells Increase Before Human Immunodeficiency Virus Rebound After Analytical Antiretroviral Treatment Interruption. The Journal of Infectious Diseases, 221(7), 1146–1155.
• Hogan, L. E., Vasquez, J., Hobbs, K. S., Hanhauser, E., Aguilar-Rodriguez, B., Hussien, R., Thanh, C., Gibson, E. A., Carvidi, A. B., Louis, Khan, S., Trapecar, M., Shomyseh Sanjabi, Somsouk, M., Stoddart, C. A., Kuritzkes, D. R., Deeks, S. G., & Henrich, T. J. (2018). Increased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30. PLOS Pathogens, 14(2), e1006856–e1006856.